Business Description
OliX Pharmaceuticals Inc
No. 1014 Gwanggyo Ace Tower 1, Daehak 4-ro, Yeongtong-gu, Gyeonggi, Suwon, KOR, 16226
Compare
Compare
Traded in other countries / regions
226950.Korea
Description
OliX Pharmaceuticals Inc is a clinical stage biotechnology company. It is engaged in developing RNA interference (RNAi) technology therapeutics for dermal, ophthalmic and pulmonary diseases. The company's pipeline products include OLX101, OLX201, OLX301, OLX102, and others.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.11 | |||||
| Equity-to-Asset | 0.13 | |||||
| Debt-to-Equity | 3.71 | |||||
| Debt-to-EBITDA | -1.33 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0.21 | |||||
| Beneish M-Score | -2.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 117.7 | |||||
| 3-Year EBITDA Growth Rate | -47 | |||||
| 3-Year EPS without NRI Growth Rate | -48.2 | |||||
| 3-Year FCF Growth Rate | -57.3 | |||||
| 3-Year Book Growth Rate | -31.6 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.21 | |||||
| 9-Day RSI | 53.38 | |||||
| 14-Day RSI | 52.52 | |||||
| 6-1 Month Momentum % | -24.34 | |||||
| 12-1 Month Momentum % | -52.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.05 | |||||
| Quick Ratio | 1.04 | |||||
| Cash Ratio | 0.98 | |||||
| Days Sales Outstanding | 4.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.8 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 105.06 | |||||
| Operating Margin % | -551.97 | |||||
| Net Margin % | -608.96 | |||||
| ROE % | -120.95 | |||||
| ROA % | -39.92 | |||||
| ROIC % | -68.28 | |||||
| ROC (Joel Greenblatt) % | -179.14 | |||||
| ROCE % | -53.86 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 63.5 | |||||
| PB Ratio | 31.47 | |||||
| Price-to-Tangible-Book | 39.86 | |||||
| EV-to-EBIT | -10.5 | |||||
| EV-to-EBITDA | -11.15 | |||||
| EV-to-Revenue | 62.71 | |||||
| EV-to-FCF | -7.02 | |||||
| Earnings Yield (Greenblatt) % | -9.52 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₩) | 5,007.167 | ||
| EPS (TTM) (₩) | -2224 | ||
| Beta | 1.35 | ||
| Volatility % | 37.08 | ||
| 14-Day RSI | 52.52 | ||
| 14-Day ATR (₩) | 1341.131735 | ||
| 20-Day SMA (₩) | 22125 | ||
| 12-1 Month Momentum % | -52.77 | ||
| 52-Week Range (₩) | 19150 - 51000 | ||
| Shares Outstanding (Mil) | 13.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OliX Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||